蔡肇栩;梁龙清;杨晓珊;吴伟英;冯昌文;卢俊霖;李丽;林红宁;简晓顺;陈雄刚;
CAI Zhaoxu;LIANG Longqing;YANG Xiaoshan;WU Weiying;FENG Changwen;LU Junlin;LI Li;LIN Hongning;JIAN Xiaoshun;CHEN Xionggang;Department of Pharmacy,The First people's Hospital of Zhaoqing City;Department of Pharmacy,Cancer Center of Guangzhou Medical University;

• 1:肇庆市第一人民医院药学部
• 2:广州医科大学附属肿瘤医院药学部

摘要(Abstract)：

目的探索PAI-1与F5基因多态性检测在重症医学科(ICU)患者静脉血栓风险评估中的应用价值。方法选取我院ICU 2019年6月～2020年2月行静脉血栓风险基因检测并经彩色多普勒超声血流成像确诊有不同程度下肢深静脉血栓形成的患者90例,作为VTE组。同期选取排除静脉血栓高风险及经彩色多普勒超声血流成像诊断下肢静脉血栓为阴性的90例患者作为对照组。采用数字荧光染色原位杂交检测法对PAI-1基因4G/5G与F5基因G/A多态性进行检测。结果 PAI-1基因4G/5G的3种基因型在VTE组和对照组的分布频率分别为:4G4G型(41.11%,24.44%)、4G5G型(47.78%,55.56%)和5G5G型(11.11%,20.00%)。其VTE组患者基因型分布频率在与对照组患者基因型分布比较,差异有统计学意义(P<0.05)。F5基因在VTE组和对照组的分布频率分别为GG型(100%,98.89%) GA型(0%,1.11%)只有对照组1例为GA基因型,其余179例全为GG基因型。为通过非条件logistic回归模型分析,对PAI-1 5G5G基因型患者相比,4G4G基因型患者静脉血栓发生风险升高4.7倍(95%CI=1.926～11.517),4G5G基因型患者静脉血栓发生风险升高2.4倍(95%CI=1.051～5.518),静脉血栓发生率差异具有统计学意义(P<0.05)。结论 PAI-1基因4G/5G多态性对ICU患者静脉血栓风险形成的预测具有重要的临床意义。
OBJECTIVE To explore the application value of PAI-1 and F5 gene polymorphism detection in the risk of venous thromboembolism assessment in ICU patients. METHODS From June 2019 to February 2020,a total of 90 patients who were tested for venous thrombosis risk gene and diagnosed by color doppler ultrasound blood flow imaging with different degrees of deep venous thromboembolism in our hospital,were selected retrospectively as the VTE group.In the same period,90 patients who excluded high risk of venous thromboembolism and were negative for venous thromboembolism by color doppler ultrasound flow imaging were selected as the control group.Fluorescence staining in situ hybridization was used to detect the PAI-1 gene 4 G/5 G and F5 gene G/A polymorphism.RESULTS The distribution frequencies of the three genotypes of PAI-1 gene 4 G/5 G in the VTE group and the control group were4 G4 G genotype( 41. 11%,24. 44%),4 G5 G genotype( 47. 78%,55. 56%) and 5 G5 G genotype( 11. 11%,20. 00%),respectively. The frequency of the genotype distribution of patients in the VTE group was statistically different from that of the control group( P<0.05).The distribution frequency of F5 gene in VTE group and control group were GG genotype( 100%,98.89%) and GA genotype( 0%,1.11%).Only one case of control group was GA genotype,and the remaining 179 cases were all GG genotype.Analyzed by unconditional logistic regression model,compared with patients with PAI-1 5 G5 G genotype,the risk of venous thrombosis in patients with 4 G4 G genotype was increased 4.7 times( 95% CI = 1. 926-11. 517),and the risk of venous thrombosis in patients with 4 G5 G genotype was increased 2. 4 times( 95% CI = 1. 051-5. 518). There are statistically significant differences in the incidence of venous thromboembolism( P < 0. 05).CONCLUSION PAI-1 gene 4 G/5 G polymorphism has important clinical significance for predicting the risk of venous thrombosis to ICU patients.

关键词(KeyWords)： PAI-1;F5;重症医学科;静脉血栓;基因多态性
PAI-1;F5;ICU;venous thrombosis;gene polymorphism

Abstract:

Keywords:

基金项目(Foundation): 广东省药学会科学研究基金(2019JZ02)

作者(Author): 蔡肇栩;梁龙清;杨晓珊;吴伟英;冯昌文;卢俊霖;李丽;林红宁;简晓顺;陈雄刚;
CAI Zhaoxu;LIANG Longqing;YANG Xiaoshan;WU Weiying;FENG Changwen;LU Junlin;LI Li;LIN Hongning;JIAN Xiaoshun;CHEN Xionggang;Department of Pharmacy,The First people's Hospital of Zhaoqing City;Department of Pharmacy,Cancer Center of Guangzhou Medical University;

Email:

DOI:

参考文献(References)：

• [1]Samuel Z,Goldhaber.Risk factors for venous thromboembolism[J].Archives of Internal Medicine,2010,56(1):1-7．
• [2]Beye A,Pindur G.Clinical significance of factor V leiden and prothrombin G20210A-mutations in cerebral venous thrombosis-comparison with arterial ischemic stroke[J].Clin Hemorheol Microcirc,2017,67(3/4):261-266．
• [3]张惠，马渝，文玉明，等．重症患者静脉血栓栓塞风险和预防的回顾性分析[J]．中华急诊医学杂志，2013,22(5):517-520．
• [4]周诚，木合拜提·买合苏提．肺栓塞致右心功能不全及肺动脉高压的相关性研究[C]∥中华医学会新疆维吾尔自治区医学会．中华医学会放射学分会全国磁共振学术大会论文集，2010:836-839．
• [5]邵丹，毕铁琳，于倩，等．临床药师在“静脉血栓栓塞症防控体系”构建中的药学实践[J]．实用药物与临床，2020,23(4):362-365．
• [6]Muller G,Fritz E,Them C.Translation of the"Autar Deep Vein Thrombosis Scale"to assess the risk of thrombosis[J].Pflege Zeitschrift,2008,61(2):94-99．
• [7]Guyatt G H,Akl E A,Crowther M,et al.Existutivesummary:antithrombotie therapy and prevention of somrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(Suppl 2):7S-47S．
• [8]张俊丽，蔡卫新，梁建姝，等．3种工具预测不同科室住院病人DVT形成的对比研究[J]．护理研究:中旬版，2015 (6):2146-2148．
• [9]Autar R.The management of deep vein thrombosis:the Autar DVTrisk assessment scale revisited[J].Journal of Orthopaedic Nursing,2003,7(3):114-124．
• [10]Ahmed A B,Koster A,Lance M,et al.European guidelines on perioperative venous thromboembolism prophylaxis:Cardiovascular and thoracic surgery[J].Eur J Anaesthesiol,2018,35(2):84-89．
• [11]Miri M,Goharani R,Sistanizad M,et al.Deep vein thrombosis among intensive care unit patients;an epidemiologic study[J].E-mergency,2017,5(1):e13．
• [12]孙荣凤．Autar量表在重型颅脑损伤患者的应用观察[J]．当代临床医刊，2016,29(5):2535-2535．
• [13]Liang Z,Jiang W,Ouyang M,et al.PAI-1 4G/5G polymorphism and coronary artery disease risk:A meta-analysis[J].International Journal of Clinical and Experimental Medicine,2015,8(2):2097-2107．
• [14]Boekholdt S M,Bijsterveld N R,Moons A H M,et al.Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction:A Systematic Review[J].Circulation,2001,104(25):3063-3068．
• [15]Morgan J A,Bombell S,Mcguire W.Association of Plasminogen Activator Inhibitor-Type 1 (-675 4G/5G) Polymorphism with Pre-Eclampsia:Systematic Review[J].PLOS ONE,2013,8(2):e56907．
• [16]Tja rnlund-Wolf A,Brogren H,Lo E H,et al.Plasminogen activator inhihibitor-1 and thrombotic cereberovascular diseases[J].Stroke,2012,43:2833-2839．
• [17]张海罡，王怡，熊东方，等．F5及PAI-1基因多态性联合检测在烧伤多次手术患者深静脉血栓形成风险评估中的应用[J]．陕西医学杂志，2018,47(7):843-845．
• [18]Stegnar M,Uhrin P,Peternel P,et al.The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1(PAI-1)gene:relationship to plasma PAI-1 level in venous thromboembolism[J].Thromb Haemost,1998,80(5):975-979.